Leerink Partnrs Estimates Biogen’s Q2 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at Leerink Partnrs decreased their Q2 2025 EPS estimates for Biogen in a report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will post earnings of $4.05 per share for the quarter, down from their previous forecast of $4.10. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Leerink Partnrs also issued estimates for Biogen’s Q3 2025 earnings at $3.96 EPS, Q4 2025 earnings at $4.19 EPS, FY2025 earnings at $14.90 EPS and FY2026 earnings at $16.30 EPS.

Several other equities analysts have also recently weighed in on the stock. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price objective (down previously from $138.00) on shares of Biogen in a research note on Tuesday, February 18th. Bank Of America (Bofa) decreased their target price on Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a report on Tuesday, February 11th. Scotiabank cut their price target on Biogen from $244.00 to $224.00 and set a “sector outperform” rating for the company in a report on Thursday, February 13th. Canaccord Genuity Group reduced their target price on shares of Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Finally, Truist Financial dropped their price target on shares of Biogen from $220.00 to $210.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Eighteen research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $213.15.

Biogen Price Performance

NASDAQ BIIB opened at $116.98 on Tuesday. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. Biogen has a 1-year low of $110.04 and a 1-year high of $238.00. The stock has a market capitalization of $17.12 billion, a price-to-earnings ratio of 10.45, a PEG ratio of 1.51 and a beta of 0.06. The business’s fifty day moving average price is $135.71 and its 200-day moving average price is $152.96.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Hedge Funds Weigh In On Biogen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. raised its holdings in shares of Biogen by 13,574.7% during the fourth quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company’s stock valued at $407,919,000 after acquiring an additional 2,648,024 shares during the last quarter. Norges Bank purchased a new position in Biogen in the 4th quarter valued at $355,569,000. Van ECK Associates Corp boosted its stake in Biogen by 977.9% during the 4th quarter. Van ECK Associates Corp now owns 1,066,460 shares of the biotechnology company’s stock worth $163,083,000 after purchasing an additional 967,523 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Biogen by 30.6% during the fourth quarter. Invesco Ltd. now owns 2,128,807 shares of the biotechnology company’s stock worth $325,537,000 after buying an additional 499,074 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Biogen by 982.0% in the fourth quarter. AQR Capital Management LLC now owns 539,692 shares of the biotechnology company’s stock valued at $81,914,000 after buying an additional 489,811 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the transaction, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. This represents a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by insiders.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.